Swampscott, MA, United States of America

Louise Clare Kirman

This inventor holds 11 USPTO granted patents and 11 published patent applications and 6 EPO patents. Top assignees: Novartis Ag, Cedilla Therapeutics, Inc.. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Louise Clare Kirman. Retrieved from https://idiyas.com/inventor/louise-clare-kirman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 11)

% Patents Active = 27.3

EPO Patents = 6 (Patent Applications = 14)

Average Co-Inventor Count = 7.1

ph-index = 2

Forward Citations = 11(Granted Patents)

Location History:

Marblehead, MA (US) (2010 - 2012)
Cambridge, MA (US) (2011 - 2014)
Swampscott, MA (US) (2011 - 2024)

Company Filing History:

Cedilla Therapeutics, Inc.

patents

Years Active: 2010-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655150 - TEAD INHIBITORS AND USES THEREOF (2026-06-16),

2. 12065445 - CDK2 inhibitors and methods of using the same (2024-08-20),

3. 12053459 - CDK2 inhibitors and methods of using the same (2024-08-06),

4. 9789118 - Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof (2017-10-17),

5. 8697739 - Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof (2014-04-15),

6. 8394858 - Cyclohexane derivatives and uses thereof (2013-03-12),

7. 8252931 - Thiazolo[5,4-B]pyridine glucokinase activators (2012-08-28),

8. 8129541 - 5-phenylthiazole derivatives and use as PI3 kinase inhibitors (2012-03-06),

9. 8084448 - Organic compounds (2011-12-27),

10. 8017608 - 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors (2011-09-13),

11. 7687637 - 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors (2010-03-30),

Title: Louise Clare Kirman: Innovator in CDK2 Inhibition

Introduction

Louise Clare Kirman is a prominent inventor based in Swampscott, MA (US). She has made significant contributions to the field of pharmacology, particularly in the development of CDK2 inhibitors. With a total of 11 patents to her name, her work has been instrumental in advancing treatments for various diseases related to CDK2 activity.

Latest Patents

Among her latest patents, Kirman has developed compounds that serve as CDK2 inhibitors. The first patent provides compounds according to a specific formula, along with methods for using these compounds to inhibit CDK and treat related diseases and disorders. The second patent focuses on Cyclin-dependent kinase 2 (CDK2) inhibiting chemical compounds and their applications in inhibiting CDK2 activity. These innovations are crucial for the development of new therapeutic strategies.

Career Highlights

Throughout her career, Kirman has worked with notable companies such as Novartis AG and Cedilla Therapeutics, Inc. Her experience in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of her notable coworkers include Gregory Raymond Bebernitz and David Weninger Barnes. Their collaborative efforts have further enhanced the impact of her research and innovations.

Conclusion

Louise Clare Kirman is a distinguished inventor whose work in CDK2 inhibitors has the potential to transform treatment options for various disorders. Her contributions to the field are invaluable and continue to inspire future innovations.

Profile summary based on public USPTO records.